Search clinical trials for: Darbepoetin alfa

Total 3066 results

Region Stockholm

Not yet recruiting

The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (FOXTROT)

Diabetes Complications | Diabetes; Nephropathy (Manifestation)

Sweden
Amgen

Completed

Chemotherapy Related Anemia

Anemia | Non-Myeloid Malignancies
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Chong Kun Dang Pharmaceutical

Completed

CKD-11101 Phase 3 SC Study

Anemia of Chronic Kidney Disease
Royal Alexandra Hospital
University of Alberta

Completed

Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury

Traumatic Brain Injury

Canada
University of New Mexico
University of Utah

Completed

Mild Encephalopathy in the Newborn Treated With Darbepoetin (MEND)

Hypoxic-Ischemic Encephalopathy Mild | Neonatal Encephalopathy

United States
The Hospital for Sick Children

Completed

Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure

Kidney Failure, Chronic

Canada
Amgen

Completed

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Chronic Kidney Disease
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy

Anemia
Kyowa Kirin Co., Ltd.

Completed

A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients

Anemia

Japan
Amgen

Completed

Heart Failure and Anemia

Heart Failure | Anemia
Amgen

Completed

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Lymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia
Amgen

Completed

Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

Anemia | Kidney Disease
Amgen

Completed

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Anemia | Chronic Kidney Disease

France, Italy, United Kingdom, Belgium, Hungary, Spain, Israel, Portugal, Bulgaria, Serbia, Poland, Romania, Greece, Australia, Denmark, Russian Federation, Slovakia, Germany, Latvia, Estonia, Slovenia, Czech Republic, Mexico
Amgen

Completed

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

Cancer
Jonsson Comprehensive Cancer Center
Amgen

Completed

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant Condition

United States
Amgen

Completed

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

Chronic Kidney Disease | Kidney Disease
Imperial College London

Recruiting

Darbepoetin in Neonatal Encephalopathy Trial (EDEN)

Neonatal Encephalopathy

United Kingdom
Amgen

Completed

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes
Amgen

Completed

A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects

Anemia | Congestive Heart Failure
Amgen

Completed

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

Chronic Kidney Disease | Kidney Disease
Amgen

Completed

Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Neoplasms | Anemia
Herning Hospital
Amgen

Completed

The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery

Colorectal Cancer

Denmark
Merck Sharp & Dohme LLC

Terminated

A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)

Anemia | Chronic Kidney Disease
Amgen

Completed

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Cancer | Anemia
Kyowa Kirin Co., Ltd.

Completed

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Anemia

Japan
Amgen

Completed

Fixed Dose NESP Study in Subjects With CRI

Pre-Dialysis
Amgen

Completed

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Anemia
Amgen

Completed

Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects

Anemia
Amgen

Completed

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Anemia
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Astellas Pharma Inc

Completed

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Renal Anemia Associated With Chronic Renal Failure (CRF)

Japan
Hoffmann-La Roche

Completed

COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Anemia

Australia
Amgen

Completed

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

Kidney Disease
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Amgen

Completed

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Anemia | Non-Small Cell Lung Cancer
Amgen

Completed

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Breast Cancer | Anemia
Amgen

Completed

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Genital Neoplasms, Female | Anemia | Gynecological Malignancies
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Neoplasms | Cancer | Anemia

United States
Zydus Lifesciences Limited

Completed

Desidustat in the Treatment of Anemia in CKD (DREAM-ND)

Anemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4

India
Groupe Francophone des Myelodysplasies

Unknown

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

France
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Hallym University Medical Center

Recruiting

High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Anemia

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
UMC Utrecht
The Hospital for Sick Children; Alberta Children's Hospital

Recruiting

Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration (DINOSAUR)

Perinatal Stroke | Neonatal Stroke | PAIS

Netherlands
Ortho Biotech Products, L.P.

Completed

Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

Anemia | Chemotherapy
VA Office of Research and Development

Active, not recruiting

Mechanisms of EPO-induced Hypertension (EPIC)

Anemia | Chronic Kidney Disease | Blood Pressure

United States
Amgen

Completed

Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Anemia | Congestive Heart Failure
Mayo Clinic
National Cancer Institute (NCI)

Completed

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
St. Bartholomew's Hospital

Unknown

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United Kingdom

3

Subscribe